Autonomix Medical raises $2.5M through warrant exercise agreements

Autonomix Medical Inc. (NASDAQ: AMIX) announced it has entered into agreements with warrant holders for the immediate exercise of outstanding warrants to purchase up to 1,477,596 shares of common stock at a reduced exercise price of $1.723 per share, generating approximately $2.5 million in gross proceeds.

The warrants were originally issued in November 2024 and are registered under an effective Form S-1 registration statement. Ladenburg Thalmann & Co. Inc. is serving as placement agent for the transaction, which is expected to close on July 23, 2025.

In exchange for the immediate warrant exercise, the company will issue new unregistered warrants exercisable for the same number of shares at the same $1.723 exercise price. The new warrants will be exercisable immediately upon issuance and have a term of five and one-half years.

Some warrant holders agreed to prepay $1.722 of the exercise price and will receive amended warrants with a $0.001 exercise price for the prepaid portion.

The company stated it intends to use net proceeds for working capital and general corporate purposes. The new warrants were offered through a private placement under Securities Act exemptions and have not been registered with the Securities and Exchange Commission.

Autonomix Medical develops medical device technology focused on nerve-targeted treatments, with initial development centered on pain management applications including pancreatic cancer treatment. The company's catheter-based microchip sensing technology is investigational and has not been cleared for marketing in the United States.

You May Also Be Interested In

• SOBRsafe raises $3.1M through warrant exercise at reduced price
• Goldman Sachs Starts Excelerate Energy Inc (EE) at Buy
• Eos Energy wins Golden Dome defense contract for energy storage